Biopharma
ByEli Lilly Delivers Transformational Growth in 2025, Anchored by Metabolic Leadership and Innovation Execution
Indianapolis, IN – February 2026 – Eli Lilly and Company reported exceptional full-year financial and operational performance in…
Merck Reinforces Oncology Leadership and Therapeutic Area Depth with Robust 2025 Performance
Rahway, NJ – February 2026 – Merck & Co., Inc. reported strong full-year 2025 financial and operational performance,…
AbbVie Accelerates Portfolio-Led Growth in 2025 and Strengthens Its Long-Term Therapeutic Leadership
North Chicago, IL – February 2026 – AbbVie Inc. reported a strong full-year financial performance in 2025, underscoring…
Did Abivax Just Quash Acquisition Rumors by Eli Lilly — and What It Means for Its IBD Breakthrough Asset?
January 26, 2026 — Paris & Global — Abivax SA, the French clinical‑stage biotechnology company, this week publicly dismissed speculation…
How Does AstraZeneca Transform ADC Dominance Into an $80 Billion Revenue Juggernaut by 2030?
AstraZeneca masterminds an “oncology everywhere” empire through surgical deployment of 20+ late-stage novel molecular entities across oncology (43% revenue), CVRM,…
How Does Roche’s TA-Wise Fortress Strategy Conquer 2030 LOE Cliffs Amid Obesity Wars?
Roche orchestrates a pharma-diagnostics juggernaut, surgically allocating 60% of R&D across five therapeutic arenas while weaponizing FoundationOne/Flatiron (covering 60% of pipeline…
